Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Furlong

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
CHEST Critical Care|December 15, 2025
Epidemiologic Characteristics and Management of Sepsis Among Previously Healthy PatientsRachel K Hechtman, Megan E Heath, Jennifer K Horowitz, et al.
Biomaterials|October 11, 2021
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvantLaura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biomaterials|May 19, 2026
Corrigendum to 'Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant' [Biomaterials, 128 (2021), 121159]Laura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
ACS Central Science|September 1, 2021
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular ImmunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Nature Communications|January 21, 2022
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2Lamiaa El-Shennawy, Andrew D Hoffmann, Nurmaa Khund Dashzeveg, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
CHEST Critical Care|December 15, 2025
Epidemiologic Characteristics and Management of Sepsis Among Previously Healthy PatientsRachel K Hechtman, Megan E Heath, Jennifer K Horowitz, et al.
Biomaterials|October 11, 2021
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvantLaura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biomaterials|May 19, 2026
Corrigendum to 'Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant' [Biomaterials, 128 (2021), 121159]Laura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
ACS Central Science|September 1, 2021
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular ImmunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Nature Communications|January 21, 2022
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2Lamiaa El-Shennawy, Andrew D Hoffmann, Nurmaa Khund Dashzeveg, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Pageof 2